MT-I (Melanotan I) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that has been studied for its ability to influence skin pigmentation.

While there has been interest in MT-I for cosmetic tanning and photoprotection concepts, its regulatory status and approved uses differ across regions, and many commercial preparations fall outside standard drug pathways.

MT-I activates melanocortin receptors involved in melanogenesis. High-level effects include:

• Stimulating melanin production in the skin
• Potentially affecting related melanocortin pathways with broader physiologic roles

The clinical significance of these actions, particularly for long-term photoprotection or other outcomes, continues to be explored.

MT-I has been investigated in selected medical and photoprotection contexts, but its role in clinical practice is limited and region-dependent. Many references to MT-I occur in cosmetic or lifestyle discussions rather than evidence-based guidelines.

Any consideration of MT-I should be framed around local regulations and current data, and should distinguish between research and cosmetic marketing claims.

Reported effects include nausea, flushing, and changes in existing pigmented lesions. Long-term consequences, including potential interactions with skin cancer risk, are not fully understood.

Dermatologic surveillance and consultation with qualified clinicians are important considerations when evaluating products that alter pigmentation.

MT-I (Afamelanotide) is less potent than MT-II but has a more favorable side effect profile.

This information summarizes commonly discussed research and clinical practices.

In catalogs, MT-I may appear as a standalone vial or as part of broader cosmetic or photoprotection product bundles.

Listings on this site are structural and do not recommend particular cosmetic or protocol uses.

Research on MT-I has investigated its potential to modify pigmentation and photoprotection endpoints. Study designs and populations vary, and long-term outcome data are limited.

Interpretation of this literature requires attention to evolving dermatologic standards and risk–benefit considerations.

Future FAQs may address how melanocortin analogs fit into discussions of sun exposure, pigmentary disorders, and cosmetic tanning. Answers will be high-level and non-prescriptive.